Post by Novo Nordisk

#PRESS: New data from our cardiometabolic portfolio and pipeline will be showcased at the upcoming 2026 Scientific Sessions of the American Diabetes Association® (ADA), taking place in New Orleans, June 5–8, 2026. From amylin-based pipeline candidates to continued expansion of our portfolio, we are building on the established and unique profile of semaglutide. Learn more in the press release here: https://lnkd.in/d66yYHae